FIGURE 6.

Correlations of anti-vimentin autoantibody responses and clinical manifestations of IPF. (A) Plasma anti-vimentin autoantibody concentrations were inversely correlated with FVC and DLCO (as percentages of predicted values) in both IPF patient cohorts. (B) Transplant-free survival during the next 2 y was similarly reduced in both cohorts among the IPF patients in the tertiles with the highest circulating anti-vimentin levels. (C) Measures of anti-vimentin and anti-HSP70 autoantibodies were available in a limited number of IPF patients. Those who had greater than average levels of both autoantibodies (Both High, n = 10) had lesser FVC percentage predicted than did the other patients (Other) who had only a single or no increased autoantibody concentration. There was no significant difference between FVC percentage predicted of patients with a single increased autoantibody (anti-vimentin or anti-HSP70) (n = 24) and those in whom both autoantibodies were below mean levels (n = 8) (64 ± 18% versus 69 ± 12%, respectively). (D) Transplant–free survival was also much worse in this IPF subpopulation who had increased levels of both autoantibodies compared with the other subjects. *p = 0.017.